No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BDRX Biodexa Pharmaceuticals
- 0.7520
- -0.0681-8.30%
Close Apr 19 16:00 ET
- 0.7999
- +0.0479+6.37%
Post 19:41 ET
3.20MMarket Cap-1P/E (TTM)
0.8318High0.7510Low151.71KVolume0.8250Open0.8201Pre Close119.95KTurnover5.76%Turnover RatioLossP/E (Static)4.25MShares21.616052wk High0.48P/B1.98MFloat Cap0.719352wk Low--Dividend TTM2.63MShs Float587200.0000Historical High--Div YieldTTM9.85%Amplitude0.7193Historical Low0.7900Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Biodexa Pharmaceuticals Reports Preliminary FY Results
Express News | Biodexa Pharmaceuticals Sees Prelim. FY23 EPS £(0.02)
Express News | Biodexa Pharmaceuticals Says We Have The Resources To Deliver Two Sets Of Preclinical Data And Three Sets Of Clinical Data In 2024; Our Development Pipeline Now Includes Five Programs, Of Which Four Are At Clinical Stage; With Pipeline Stronger Than It Ha
Express News | Biodexa Pharmaceuticals Sees Prelim. FY23 Revenue £0.38M
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading
European equities traded in the US as American depositary receipts were treading water in Thursday morning session, nudging 0.006% higher to 1,330.06 on the S&P Europe Select ADR Index. From continent
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading
European equities traded in the US as American depositary receipts were trending lower Wednesday morning, falling 0.3% to 1,330.47 on the S&P Europe Select ADR Index. From continental Europe, the gain
Comments
News! Like!
$Biodexa Pharmaceuticals(BDRX.US$ Biodexa Pharmaceuticals Says We Have The Resources To Deliver Two Sets Of Preclinical Data And Three Sets Of Clinical Data In 2024; Our Development Pipeline Now Includes Five Programs, Of Which Four Are At Clinical Stage; With Pipeline Stronger Than It Has Ever Been, We Are Enthusiastic About The Potential For Our Company In 2024 And Beyond
2
$Biodexa Pharmaceuticals(BDRX.US$ this stock scary, went down so much
Healthcare Company's Treatment Extends Brain Cancer Survival
The Lifesaving Promise of MTX110: How Biodexa's Breakthrough Could Change Your Future.
In the realm of health and survival, few diagnoses are as daunting as Glioblastoma Multiforme (GBM), the most aggressive form of brain cancer known to adults. Traditionally, those afflicted with GBM have faced grim prospects, with life expectancies typically ranging between 12 to 18 months post-diagnosis. However, a beacon of hope shines from Biodexa...
In the realm of health and survival, few diagnoses are as daunting as Glioblastoma Multiforme (GBM), the most aggressive form of brain cancer known to adults. Traditionally, those afflicted with GBM have faced grim prospects, with life expectancies typically ranging between 12 to 18 months post-diagnosis. However, a beacon of hope shines from Biodexa...
3
$Biodexa Pharmaceuticals(BDRX.US$ Lost steam already???
1
$Biodexa Pharmaceuticals(BDRX.US$ lets get a push to $2 today
1
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg